Skip to content

Erasca, Inc. ERAS Investing Cash Flow

Investing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$131M+73.7%
Eli Lilly logo
Eli LillyLLY
-$3.92B-16.8%
Pfizer logo
PfizerPFE
$785M-76.0%
Amgen logo
AmgenAMGN
-$716M-60.2%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$172.62M+1,182%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$9.64M-68.5%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s investing cash flow?
Erasca, Inc. (ERAS) reported investing cash flow of -$243.83M in Q1 2026.
How has Erasca, Inc.'s investing cash flow changed year-over-year?
Erasca, Inc.'s investing cash flow decreased by 811.6% year-over-year, from $34.27M to -$243.83M.
What is the long-term trend for Erasca, Inc.'s investing cash flow?
Over 3 years (2021 to 2025), Erasca, Inc.'s investing cash flow has grown at a 15.8% compound annual growth rate (CAGR), from -$64.59M to $100.43M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.